Last reviewed · How we verify

Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

NCT06176235 PHASE2 WITHDRAWN

A randomized, open-label, multicenter study to compare the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

Details

Lead sponsorPeking University People's Hospital
PhasePHASE2
StatusWITHDRAWN
Start dateTue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionMon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

China